Martinsried, Germany

Suppremol Gmbh


USPTO Granted Patents = 9



Forward Citations = 7

Loading Chart...
Loading Chart...

16 inventors (with patents filed for the assignee):

goldMedal Peter Sondermann (8 out of 15 patents)

silverMedal Thomas Pohl (6 out of 7 patents)

bronzeMedal Dominik Ter Meer (4 out of 4 patents)

4.  Anna Carle (2 out of 2 patents)

5.  Nicole Rieth (2 out of 2 patents)

6.  Carolin Direnberger (1 out of 1 patent)

7.  Martina Mueller (1 out of 1 patent)

8.  Reno Winter (1 out of 1 patent)

9.  Daniela Ehehalt (1 out of 1 patent)

10.  Peter Buckel (1 out of 6 patents)

11.  Sascha Tillmanns (1 out of 1 patent)

12.  Ingrid Berger (1 out of 1 patent)

13.  Ralf Ludwig (1 out of 1 patent)

14.  Uwe Jacob (1 out of 8 patents)

15.  Bruce David Wines (1 out of 2 patents)


9 patents:

Company Overview
Suppremol GmbH is a biotechnology company focused on the development of innovative treatments for autoimmune diseases. With a strong emphasis on research and development, the company is dedicated to advancing novel therapies that target the underlying causes of autoimmune disorders. Their pipeline includes promising candidates for diseases such as rheumatoid arthritis, lupus, and multiple sclerosis. Suppremol is committed to improving the lives of patients and addressing the unmet medical needs in the field of autoimmune diseases.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

9 Patents

#11 in Martinsried

#4,072 in Germany

Martinsried, DE
Martinsried, Germany
Forward Citations = 7

16 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Suppremol Gmbh. Retrieved from https://idiyas.com/company/suppremol

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…